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Abstract 
Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder characterized by -motor neuron loss in 
the spinal cord anterior horn.  SMA results from deletion or mutation of the Survival Motor Neuron 1 gene 
(SMN1) and retention of SMN2.  A single nucleotide difference between SMN1 and SMN2 results in exclusion 
of exon 7 from the majority of SMN2 transcripts, leading to decreased SMN protein levels and development of 
SMA.  A series of splice enhancers and silencers regulate incorporation of SMN2 exon 7; these splice motifs 
can be blocked with antisense oligomers (ASOs) to alter SMN2 transcript splicing.  We have evaluated a 
morpholino oligomer against ISS-N1 (HSMN2Ex7D(-10,-29)), and delivered this morpholino (MO) to postnatal 
day 0 (P0) SMA pups (Smn -/-, SMN2+/+, SMN∆7 +/+) by intracerebroventricular (ICV) injection.  Survival was 
increased markedly from 15 days to over 100 days.  Delayed CNS MO injection has moderate efficacy, and 
delayed peripheral injection has mild survival advantage, suggesting that early CNS ASO administration is 
essential for SMA therapy consideration.  ICV treatment increased full-length SMN2 transcript as well as SMN 
protein in neural tissue, but only minimally in peripheral tissue.  Interval analysis shows a decrease in 
alternative splice modification over time.  We suggest that CNS increases of SMN will have a major impact on 
SMA, and an early increase of SMN level results in correction of motor phenotypes.  Last, the early 
introduction by intrathecal delivery of morpholino oligomers is a potential treatment for SMA patients. 
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Introduction 
Spinal Muscular Atrophy (SMA), the leading cause of hereditary infant mortality (1), is an autosomal 
recessive disorder characterized by -motor neuron loss in the anterior horn of the spinal cord (2).  SMA is 
caused by the loss or mutation of the Survival Motor Neuron (SMN1) gene and the retention of SMN2 (3, 4).  
The SMN1 and SMN2 genes essentially differ at a single nucleotide in exon 7 (C to T transition) which disrupts 
a modulator of splicing and leads to exon 7 loss in 90% of SMN2 mRNA transcripts (5-10). The SMN protein 
lacking exon 7 encoded amino acids does not oligomerize efficiently and is rapidly degraded, leading to low 
SMN levels and thus SMA (11-13). The SMN2 copy number has a major influence on the severity of the SMA 
phenotype with milder patients (Type III-IV, juvenile/adult onset) having a higher SMN2 copy number, Type II 
having intermediate SMN2 copy number,  and severe patients (Type I, infantile) having a lower SMN2 copy 
number (14, 15).   Furthermore, different SMN2 alleles that are capable of producing more SMN act as 
improved modifiers of SMA (16, 17).  Missense mutations occur in both mild and severe patients, (4, 18) such 
mutations in severe patients often disrupt the ability of SMN to oligomerize efficiently (12, 18).  In the case of  
mild missense mutations, the SMN protein is often able to interact with wild type SMN produced by SMN2, 
resulting in more functional SMN complexes (19). 
SMN forms a complex with a series of proteins called gemins, and the best characterized function of 
this complex is the assembly of Sm proteins onto snRNA, thus forming a crucial component of the splicing 
machinery (20-22).  Thus, complete loss of Smn in mice is embryonic lethal, as SnRNPs are required for gene 
splicing (23).  SMN has also been found in axons and is suggested to play a role in the axonal transport of 
mRNA (24-27).  The exact role that SMN plays in the axon is unclear (4), and motor axon growth is not 
disrupted in SMA mice models (28).  Reduced SnRNP assembly has been reported in SMA mice (29, 30), and 
certainly specific target genes could have disrupted splicing (4, 31).  Yet controversy remains as to whether 
SMA is caused by the disrupted splicing of select genes important for motor neuron circuitry, or by disrupted 
axonal maintenance (4).  It is well established that SMA is caused by insufficient SMN levels (32, 33) and thus 
current therapeutic strategies are focused on increasing the amount of SMN. 
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Mice possess only one Smn gene and the loss of this gene is embryonic lethal (23).  Thus, the 
production of mice with an SMN deficiency that models human SMA required the introduction of the SMN2 
gene.  Two copies of human SMN2 in mice lacking Smn results in mice with severe SMA that live an average 
of 5 days, while 8 copies of SMN2 results in complete rescue (34, 35). The introduction of SMN∆7, an SMN 
transgene lacking exon 7, into the severe SMA mice increases the average life span to approximately 14 days 
(36). It has recently been shown that postnatal induction of SMN can modulate SMA in SMN∆7 mice (37).  The 
SMN7 mice can therefore serve as an SMA model in which one can characterize disease modifying 
pharmacologic interventions.     
Using the SMN7 mouse model of SMA, multiple treatment strategies to increase SMN expression 
have been performed.  Targeting SMN production with various pharmacologic compounds to either activate the 
SMN promoter (38, 39) (40), or to alter exon 7 splicing patterns (41), has shown modest improvements in the 
phenotype of SMN7 SMA mice due to a relatively weak SMN induction.  Restoration of SMN using scAAV9-
SMN delivered via the facial vein in newborn SMN7 SMA mice results in rescue of the phenotype with 
survival in all cases beyond 200 days (42, 43)and in one instance  beyond 400 days(44). Thus, induction of 
SMN postnatally has a remarkable therapeutic effect.  
Antisense oligomers (ASO), including  2’-O-methyl (2’-OMe) or 2’-O-Methoxyethyl (MOE) modified 
nucleotides on a phosphorothioate backbone, peptide nucleic acids (PNA), and phosphorodiamidate 
morpholino (MO) oligomers(45-47), can be used as specific splice switching agents to alter pre-mRNA 
processing. ASOs block or enhancing motifs involved in exon recognition and splicing, including  exon splice 
enhancers (ESE) or intron splice silencers (ISS)(46-50).  Numerous regions are important in SMN2 splicing 
regulation (51), and one particularly important element is the negative splice regulator ISS-N1, a 15 nucleotide-
splice silencing motif located downstream of SMN2 exon 7 (52). An 18mer MOE chemistry ASO overlapping 
ISS-N1 effectively increases in vivo exon 7 incorporation and SMN levels through SMN2 splice modulation (53, 
54).  Intracerebroventricular (ICV) injection of this MOE at a dose of 0.58mM did increase average survival in 
SMN7 SMA mice from 14 days to 26 days  (55). However, there was evidence of toxicity with this MOE at 
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doses greater than 1.16mM.  More recently while this work was in review, Hua et al reported that peripheral 
dosing of MOEs was essential for longer survival, and propose that extra-CNS targets (i.e. peripheral) are 
required.for rescue of the SMA phenotype(56).  This assertion contradicts previous results showing the 
necessity of neuronal SMN expression using both scAAV8-SMN delivery by ICV, and transgenic approaches 
which limit SMN expression to CNS or peripheral tissue (57, 58); moreover, the authors show CNS SMN2 
splicing modulation after serial high-dose peripheral deliveries, suggesting MOE transport across the blood-
brain barrier when delivered at high doses in young mice. 
Morpholinos have a low toxicity and a wide distribution of uptake as evidenced by their extensive use 
in target gene expression knockdown in the developing zebrafish (59). Morpholinos have been used to induce 
exon skipping in Duchenne muscular dystrophy (DMD) with excellent body-wide distribution and restoration of 
dystrophin expression after systemic administration in the mdx mouse (49, 60, 61). Likewise, there have been 
encouraging clinical results in patients with DMD after morpholino administration (62-64).  
 In this study, we delivered a bolus ICV injection of a high-concentration, highly-stable morpholino 
targeted to ISS-N1 to alter SMN2 splicing and increase SMN levels. We have named this morpholino 
HSMN2Ex7D(-10,-29) (referred to as MO) based on its position relative to the exon 7 donor site. Treated SMA 
mice had improvement in weight gain, motor activity, and increased survival from 15 days to over 100 days. 
Peripheral facial vein (FV) delivery at P0, combined peripheral and ICV delivery, and dual ICV injection at P0 
and P30 produced equivalent survival.  Delayed CNS delivery (P4) had an intermediate advantage, evidence 
that earlier CNS treatment yields more robust effects, while delayed peripheral delivery after blood-brain-
barrier maturation had only modest increased survival.    
ICV injection yielded an increase in both SMN2 exon 7 incorporation and SMN protein levels in brain 
and spinal cord, while digital droplet PCR (ddPCR) showed no alteration of SMN2 splicing in peripheral tissues  
(kidney, liver, heart) with Smn+/- heterozygotes and small alterations with SMA animals. P0 FV delivery of MO 
clearly altered SMN2 splicing within the CNS, evidence that the morpholino ASO does cross the blood-brain-
barrier, but does not have effect across the CSF-blood barrier in young mouse pups.  Immunofluorescence 
analysis of lumbar spinal cord sections delineates increased SMN and dissemination of the MO to caudal CNS 
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strucutures.   These results suggest that it is essential to restore SMN levels within neurons to have a major 
impact in SMA, and long survival benefit can be obtained without significantly enhancing SMN levels in the 
periphery. It remains possible that increasing SMN expression in the ANS outside of the blood-brain-barrier 
may be required for full correction of SMA.  These results support the continued investigation of morpholino 
ASOs in the early treatment of SMA. 
 
Results 
 MO modulates exon splicing and increases SMN production 
 Mutation or steric block at the 5’ region of SMN2 intron 7 (ISS-N1) yields the greatest rates of exon 7 
inclusion (51, 52, 54). We designed our morpholino (MO) to mask this splice silencing motif (Fig. 1). A 
sequence nonspecific scramble morpholino (referred to as scMO) was manufactured with identical length and 
molecular weight to MO. To assess exon 7 splicing inclusion, we injected by ICV newborn (P0) pups of 
genotype Smn +/-; SMN2+/+; ∆7+/+ (‘heterozygotes’) with one of three doses of MO (high, middle, low dose) 
or scMO. Heterozygotes were used due to the normal phenotype (as a result of the presence of one Smn 
gene), thus controlling for additional splicing changes that could accompany an SMA mouse as well as 
secondary disease effects (e.g. poor nutrition, muscle atrophy). The availability of human specific primers and 
antibody facilitated analysis.  Injected animals were sacrificed at interval ages with collection of brain, spinal 
cord, heart, liver, and kidney tissue. The total number of mice allowed analysis of all samples in triplicate. For 
assessment of exon 7 incorporation, we performed RT-PCR and then amplified the cDNA with SMN2 specific 
primers. Amplification yields both a full-length (1491 nucleotides, top) and exon 7 deficient product (1433 
nucleotides, bottom). scMO injected animals had a strong exon 7 deficient band, and transgenic animals with 
16 copies of SMN (8SMN2 +/+; Smn -/-; HiCopy or ‘HiC’) (35) also had a relative band intensity of exon 7 
deficient greater than full-length.  All MO injected heterozygotes showed a strong band reversal (full-
length>exon 7 deficient) at all time points (P7P65) in both brain (Fig. 2A) and spinal cord (Fig. 2B).  
 Quantification of full-length SMN2 transcript was performed by both real time RT-PCR and ddPCR. The 
latter has many advantages for both quantification and detection of low levels of a specific transcript (65). The 
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sample is first partitioned into droplets, the distribution of any particular molecule (such as a specific cDNA) will 
conform to a poisson distribution. The number of droplets amplified by PCR is proportional to the concentration 
of that molecule. The end result is a count of positive droplets after the PCR has gone to completion. ddPCR 
has the ability to detect small amounts of a particular cDNA, and does not suffer from the logarithmic error 
seen in real time PCR. In our experience this method has been highly reliable in quantification when compared 
to real time PCR methods.  
We performed ddPCR of P7 pup brain and spinal cord tissue injected at P0 with either MO (2, 4, or 
6mM) or scMO (control).  Figure 2C shows the full length SMN2 response curve with escalating MO dose.  We 
next quantified by real time RT-PCR full length SMN2 transcript as a function of increasing animal age through 
P65 (Fig. 2D).  Low, middle, and high P0 MO doses yielded an increase in exon 7 incorporation at P7, with a 
stable decay through day P65.  It again should be realized that these increases in SMN2 exon 7 incorporation 
are a result of a single P0 bolus dose, delineating the robust CNS stability of the morpholino.  
 We next asked whether CNS administered MO crosses the cerebrospinal (CSF)-blood barrier and 
remains sufficiently stable in the blood stream to affect systemic structures. These experiments aimed to 
characterize the importance of CNS vs. peripheral SMN expression. SMN2 RNA splicing analysis was 
performed on CNS and systemic organs (heart, liver and kidney) one week after middle dose (4mM) MO 
injection into mice heterozygous for mouse Smn. The analysis was done by both RT-PCR and ddPCR  RT-
PCR of heart, liver, and kidney did not show subjective modulation of splicing in any visceral organ, though 
spinal cord again showed strong exon 7 incorporation (Fig. 3A).  ddPCR (Fig. 3B) revealed no significant 
splicing changes in tissue outside the nervous system after ICV delivery (liver and heart).  Furthermore, there 
was an increase in SMN2 exon 7 incorporation within the CNS after peripheral delivery, suggesting that high 
doses of MO delivered peripherally do have the ability to cross the blood-brain-barrier in the physically 
immature neonatal mouse pup. We also injected SMN7 SMA mice (n=2) by middle dose MO ICV and 
compared tissue SMN2 exon 7 incorporation to control SMN7 SMA animals (Fig. 3C).  As was seen with 
mSmn+/- heterozygotes, there were large CNS increases in full length SMN2, up to five-fold in both brain and 
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spinal cord.  There were also smaller (2-fold) increases in liver, suggesting immaturity or derangement of the 
blood-CSF barrier in SMN7 SMA mice, but again reinforcing the ‘leakiness’ of CSF barriers in neonatal pups.  
Taken together, these results are important for two reasons: first, the phenotypic changes seen in MO ICV 
injected SMA mice are most likely a result of the large amount of exon 7 splice modulation within the CNS 
relative to only modest splice modulation within the periphery, and second, peripherally administered MO in the 
neonatal mouse profoundly alters CNS SMN2 splicing.   
 We quantified SMN protein levels after P0 ICV MO injection (Fig. 4). Primary antibody detected human 
SMN and did not have affinity for mouse SMN (53).  At P7, all MO doses increased SMN levels (relative to -
actin) in both brain (Fig. 3A and 3C) and spinal cord tissue (Fig. 4B and 4D) as compared to scMO injected 
control animals.  Again, as was seen with splicing changes, there was a decrease in relative SMN levels at 
later time points.   
 P0 MO was injected by ICV into SMN∆7 SMA mice which had motor neuron specific GFP expression 
(Smn -/-; SMN2+/+; ∆7+/+; HB9:GFP), and animals were sacrificed at P0 (66). Staining of lumbar cord sections 
with human SMN specific antibody showed gems in the nucleus and SMN staining in the cytosol of both motor 
neurons and spinal cord support cells (Fig. 5). There was robust evidence of SMN in the most distal segments 
of the spinal cord parenchyma. An ICV injected lissamine-tagged morpholino also showed lumbar cord 
parenchymal distribution (Fig. S1).  
 
 MO targeting ISS-N1 extends survival in SMA animals 
 SMN7 SMA mice (Smn -/-; SMN2+/+; SMN∆7+/+) were injected by P0 ICV with either MO at low 
(n=8), middle (n=10), or high dose (n=13), or with scMO (n=8). Control mice (Smn +/+; SMN2+/+; SMN∆7+/+) 
were injected with scMO (n=30).  Animals were weighed daily, assessed for morbidity (peripheral necrosis, 
acute weight loss, bladder or bowel retention, priapism, decreased grooming) and mortality, and righting 
response was tested through P21. MO injected animals had increased survival at all concentrations (Fig. 6A), 
with median survival increasing from 15±1.1 days (scMO) to 83± 37.7 days (MO, low dose), 104±15.0 days 
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(middle dose) and 112± 6.6 days (high dose).  The survival advantage was significant for all three groups (Log 
Rank p<0.001), and was not significant between MO doses (Log Rank p>0.8); indeed, the low-dose strategy 
yielded our longest-lived mouse (161 days).  
We also injected SMN7 SMA mice with 5 µg (0.74mM, n=4) and 10 µg (1.48mM, n=3) MO (Fig. 6C); 
the former dose more closely approximates the MOE-ASO dose (0.58mM) that was reported to have some 
survival advantage (median 26 day survival) for the SMN7 SMA model in a previous ICV ASO administration 
study by Passini et al. (55) . Though it is too early in these low-dose investigations to calculate median survival, 
through P26 there is a 75% survival with 5 µg injection, and 100% survival with 10 µg.  Additionally, three mice 
were injected by ICV at P0, P1, and P2 with 135 µg MO (2 µl of 10mM MO) per dose for a total dose of 405 µg 
ICV.  These mice, currently 38 days old, are healthy and show no evidence of toxicity.  These results clearly 
indicate that long survival can be obtained with CNS delivery alone.  Mortality was not increased as a result of 
CNS cannulation or MO injection.  We did have 7 deaths among the 30 scramble control injected mice, though 
four mice were sacrificed iatrogenically due to injuries from fighting, cage flooding, and a grossly infected foot.  
No control mice died within the first week of life.  Therefore, 3 of 30 control animals died from unknown causes, 
though none displayed declining weight before death.  While it is plausible that control treatment contributed to 
this mortality, the lack of a pattern of animal decline and death in this group largely reinforces the safety of ICV 
cannulation and of the morpholino chemistry ASO. 
Treated animals had weight gain nearly parallel to control animals through ~P30 (Fig. 6B) at which time 
the mass of treated animals stabilized at ~80% that of control animals (P80 average weight of SMA treated 
animals: low=16g, middle=17g and high=19g, vs. controls=22 g). There was normalization of righting response 
within days of treatment (Fig. 7A). Forelimb and hindlimb grip-strength at P30 showed equivalent force 
generation (per animal mass) in treated SMN∆7 SMA mice as compared to controls (Fig. 7B). 
MO treated mice developed an interesting phenotype of peripheral necrosis, similar to that seen in a 
previous study of early SMN modulation (34, 38, 44).  All SMA mice had shorter tails during neonatal, 
adolescent, and early adulthood (Fig. S2A).  Beginning at ~P50, both pinna and tails of SMA mice necrosed 
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until healing granulation tissue appeared at the base of these structures (Fig. S2B). Three treated mice (one 
middle dose and two high dose) developed signs of possible autonomic nervous system dysfunction, including 
priapism, urinary retention and bowel obstruction. One middle dose and three high dose adult SMA animals 
died unexpectedly without evident morbidity (weight loss, decreased grooming, decreased activity, or urinary 
retention). These four mice weighed the most among all treated mice. This mortality suggests hyperacute 
cardiopulmonary failure as has been previously demonstrated in rescued mice of the SMN7 SMA mouse 
model (67).  
A variety of P0 injection modalities was attempted in an effort to investigate whether either a 
supplementary CNS dosing or targeting of peripheral structures (i.e. extra CNS autonomic nervous system) 
could increase animal survival and decrease necrosis.  SMA mice were injected with a high dose MO through 
the peripheral facial vein (FV), as well as a combination of ICV and FV (Fig. 8).  Additionally, another group 
received P0 ICV MO coupled with P30 stereotactic ICV injection (n=4).  All of these administration techniques 
produced impressive survival advantage equivalent to but not greater than high dose PO ICV MO (Log Rank 
p>0.09 for all pairwise comparisons).  Necrosis was not prevented or delayed in these groups.  Mice treated 
with a single peripheral injection (50 µg/g animal mass, n=3) had a median survival of 35+/-6.5 days, with a 
maximum survival of 112 days, suggesting either peripheral MO toxicity or inadequate full-length SMN 
translation.  Mice injected at P0 with both peripheral (50 µg/g) and ICV (54 µg, middle dose) MO, however, had 
substantial increases in median survival (93+/-6.4 days, n=5). These results evidence the non-toxicity of 
peripheral MO at this dose, as well as reinforce the central importance of CNS SMN2 splice modulation.  
 A cohort of SMA animals was injected at P4 by ICV (n=5) to determine the extent of phenotype 
modification with delayed delivery.  We chose delivery at P4 as this time-point approaches the latest age at 
which free-hand delivery can easily and reliably cannulate the lateral ventricle due to increasing cranial 
ossification and diminishing ventricular volume. These mice had an intermediate weight gain compared to PO 
injected SMA animals (Fig. 9A).  Median survival was also modestly improved (41±14.2 days, max 79, Log 
Rank p<0.001) (Fig. 9B). Pairwise survival comparison between P0 and P4 treated animals was also 
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significant (Log Rank p<0.006).  Thus, early administration of MO is more effective than late.  This will be an 
important consideration when moving forward towards human clinical applications (37, 68).  
 We also performed a P4 peripheral vascular injection (50 µg/g, facial vein) of MO into a group of SMA 
animals.  This group of mice (n=9) had decreased survival compared to the P4 ICV injected cohort (21+/-0.354 
days, Log Rank p<0.014) (Fig. 9C).  We surmise that the later age coupled with less direct targeting of the 
CNS motor neurons over a shortened period of time (shorter therapeutic window) resulted in greater motor 
neuron death.  This condition argues for the early CNS delivery of bare ASOs for SMA motor neuron targeting. 
 
Discussion 
 A single nucleotide alteration within exon 7 differentiates SMN1 and SMN2 capacity for full-length SMN 
protein production.  Exon 7 exclusion, as a result of modulation of SMN2 mRNA splicing (5-10), yields a 
truncated SMN that does not oligomerize efficiently, is unstable and rapidly degraded (11-13).  SMN functions 
in ensuring accurate assembly of Sm proteins onto snRNA.  This function is altered in SMA animals (19, 29) in 
direct correlation with disease severity and altered SnRNP profiles (29, 30).  However, assembly of other RNP 
complexes could also be altered, and SMN has been found in axons (4, 25).  The possibility exists for 
disruption of additional SMN functions that have not yet been elucidated, and SMA could ultimately be a result 
of splicing changes, RNA transport defects, or a combination of both.  Despite the uncertainty, it is clear that 
SMA is a disease of a reduced functional component of SMN, and thus increasing SMN at the right time and 
place is predicted to alter the disease course.  Elevating SMN in the postnatal period of SMA mice has a 
marked impact on phenotype (38, 39, 41, 43, 44, 55, 56).  Furthermore, we have shown using an inducible 
mouse that postnatal induction of SMN yields a dramatic rescue of SMA (37);  Lutz et al have reported similar 
results using a different inducible system (68).  Removal of SMN induction after 28 days has minimal effect on 
the neuromuscular system, highlighting the critical window for high SMN requirements during neonatal and 
juvenile mouse development (37).  In agreement with these studies, we have found that SMN induction early 
(P0) by a single bolus dose of MO successfully modulates SMN2 splicing and results in an impressive impact 
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on SMN∆7 SMA survival, whereas delayed delivery (P4) had a diminished impact.  These results reiterate the 
importance of early disease diagnosis and therapy. 
 Many investigative SMA treatments focus on increasing SMN protein levels.  Three strategies include 
compounds that activate the SMN2 promoter (38-40) (40), transfection of the motor neuron with an SMN 
producing viral vector (43, 44, 69), and injection of short sequence ASOs that promote modulation of splicing 
and inclusion of SMN2 exon 7 (53, 55). There are several chemistries of ASOs, including 2’-OMe, MOE, PNA, 
and morpholinos that have been used to modify RNA processing in neuromuscular disease (45-47).  Multiple 
groups have published results of CNS ASO injection in mouse models of SMA, and all have shown SMN2 
splice modulation with targeting of ISS-N1 and flanking sequences within intron 7, affirming this region as a 
strong modulator of exon 7 splice dynamics (45, 48, 53-56). The principle drawback of many of these studies is 
the relatively mild SMA phenotypic alteration.  Williams et al used a 2’-OMe ASO and noted an increased 
animal mass that declined by P12 animal sacrifice, as well as improvement in righting ability (48). The study 
was complicated by multiple cranial injections on successive days, a possible confounder for animal decline. 
Hua et al. in 2010 compared 2’-OMe and MOE oligomers targeting HSMN2Ex7D(-10 to -27) and found the 
former substantially less effective (53). 2’-OMe ASO is likely suboptimal in the treatment of SMA mice when 
used for negative regulator blocking, though it may work well when enhancing positive regulator binding. 
Baughan et al used a bifunctional 2’-OMe ASO that targeted both an intron 6 negative regulator and 
attracted SR proteins, thereby enhancing exon 7 incorporation (45).  Phenotypic advantage was again modest, 
although the authors used a more severe model of SMA (Smn-/-, SMN2+/+), and thus head-to-head 
comparison is difficult.  Hua et al showed that an ICV injected MOE oligomer against ISS-N1 altered necrosis 
phenotypes in SMN deficient mice that do not show a clear SMA motor phenotype (53).  Recently, Passini et al 
(55), using this same MOE, showed improved muscle physiology as well as survival (median of 26 days, 4 g 
dose) after ICV treatment in the SMN7 SMA model. This study showed suspected MOE toxicity at doses >8 
g (1.16mM).  The authors reported on decay rates and longitudinal splicing changes with their most 
efficacious ICV bolus dose of 4 g.  The MOE decreased from an apex of 8-10 g/g in cervical tissue to 2 g/g 
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of tissue at P16, and SMN2 splicing was effected at day 3 and 16 but returned to baseline levels by day 30.  
Due to little if any toxicity demonstrated by bolus CNS dosing of MO, we were able to administer up to 135 
g/day, and 405 g from P0-3 without adverse effect, and measured SMN2 splicing changes after single P0 
bolus of 81 g through day 65.  Therefore, the reduced CNS toxicity of morpholinos may allow for higher early 
dosing and achievement of more prolonged splicing modulation.    
While the current paper was under review Hua et al. reported the results of MOE injection targeting 
ISS-N1, and also explored various routes of delivery as well as elevated and intermittent dosing strategies 
(56).  These experiments used a different mouse model of SMA developed by Hsieh-Li et al. (34), which is 
characterized by mouse Smn lacking exon 7, thus producing a truncated transcript, as well as two copies of 
SMN2 on a chromosome.  Mice live for an average of 10-11 days and display a similar phenotype to the 
SMN7 SMA animals.  Despite many similarities, it is possible that there is unique tissue variability in SMN2 
expression between these two SMA models.  Nevertheless, the authors found minor survival advantage after a 
single P0 MOE ICV bolus dose of 20 g (2.9mM, 16 vs. 10 days). This dose is comparable to our 27 µg dose 
and resultant median survival of 83 days. It is possible that morpholinos have a longer half-life within the CNS 
and thus a longer duration of effect.   
Hua et al. reported long survival after multiple peripheral doses (median 137 days), and conclude that 
peripheral SMN restoration is essential for SMA treatment.  SMN2 splicing was modulated at high levels in 
both the periphery (liver, heart, kidney, muscle) and in the CNS (brain and spine) after peripheral delivery.  It is 
important to consider the pharmacokinetics of single versus multiple dosing, such that the latter would result in 
a more sustained therapeutic window and longer-term splice modulation over the critical early period in SMA.  
Furthermore, it is clear that both MOEs and morpholinos cross the immature blood-brain-barrier in neonatal 
mice and modulate CNS splicing, and we suspect that such translocation would not be recapitulated in human 
infants.  We propose that sustained increased levels of CNS SMN throughout a critical early window is 
essential for SMA therapy, in agreement with previous findings (44, 57, 58). 
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A morpholino ASO directed against ISS-N1 induces a robust and sustained SMN2 exon 7 
incorporation, leading to unequivocal SMN protein increases in both brain and spinal cord tissue. These 
findings correlate with an impressive SMN7 SMA survival advantage (max. 161 days, median 112 days, high 
dose MO). When compared to scAAV9-SMN injection, our weight gain and righting paralleled with these 
animals, although after viral transfection the investigators had complete survival rescue (44). ICV injection was 
performed by bolus injection at a single time (P0) or at two time points (P0 and P30) with no difference in 
survival between the two groups.  However, scAAV9-SMN animals were exposed to continuous SMN 
production due to viral-cell transduction.  The morpholino is not immune to either dilution with animal growth or 
to eventual hepatic or renal clearance, and multiple boluses or continuous MO dosing by intrathecal osmotic 
pump placed during adolescence may further prolong survival.  Alternatively, ICV dosing may miss a critical 
target such as the extra-CNS autonomic nervous system, though this seems less likely given the lack of 
increased animal survival over-and-above P0 ICV when ICV was combined with FV dosing.   
FV delivered MO at P0 also had long-term survival, though we surmise that the leaky blood-brain-
barrier in the immature mouse pup allows for translocation of ASO into the CNS, as demonstrated by ddPCR 
analysis.  MO was also delivered by FV at P4, which resulted in only mild animal rescue, suggesting that the 
critical target for SMN level modulation resides within the CNS and must be acted on early.  It may still be 
important to increase peripheral SMN, though in a more continuous fashion so as to surmount renal and 
hepatic clearance, which could be accomplished with multiple intravascular administrations by tail vein injection 
or indwelling central venous catheter placement. 
 Despite both increased inclusion of exon 7 in SMN2 transcript as well as elevated SMN protein levels at 
delayed time points (P45-65), treated SMA mice developed an interesting and time-predictable phenotype of 
ear and tail necrosis.  This necrosis pattern is not unlike that seen in less severe SMA mouse models (34) or in 
mice treated with less potent activators of SMN (38). The patterns of necrosis could represent dysfunction in 
cell populations outside of the CNS that are not fully or continuously exposed to the targeting morpholino 
delivered by bolus ICV or FV.  We have previously shown that high levels of SMN in neurons, but not in 
muscle, can increase survival of Smn-/-; SMN2+/+ mice; however, the contribution of extra-neuronal SMN has 
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not been fully elucidated (57).  The necrosis of peripheral structures, together with priapism, urinary retention 
and bowel obstruction, all serve as clinical evidence supporting potential autonomic nervous system (ANS) 
dysfunction in SMA.  A number of groups have reported cardiac bradyarrythmias, as well as dilated 
cardiomyopathy coupled with decreased contractility, in SMA mouse models (67, 70, 71), possibly due to a 
SMN deficient sympathetic nervous system leading to autonomic imbalance.  Interestingly, some of our adult 
MO treated mice died suddenly before showing any evidence of disease morbidity (i.e. weight loss, necrosis); 
we postulate that such sudden and unpredictable mortality is most likely due to acute cardiopulmonary failure 
resulting from autonomic dysfunction.  There is increasing human clinical evidence of autonomic nervous 
system imbalance in SMA.  Retrospective reports describe an increased incidence of cardiac arrhythmias and 
wall-motion abnormalities in patients with Type I SMA (72-74).  Autonomic testing, including skin vessel 
vasodilatation response and circulating norepinephrine levels, also suggest autonomic dysfunction (75).  
Morphologic and functional cardiac evaluation of MO injected mice will help elucidate the contribution of 
autonomic dysfunction on animal demise.  
 P0 injection of MO produced a striking increase in survival, delayed ICV injection had intermediate 
survival, and delayed facial vein injection yielded only mild rescue.  These results again imply the importance 
of early CNS elevations of SMN. (37, 44, 57, 68).  Previous examination of neuronal morphology in severe 
SMA embryos (Smn-/-, SMN2+/+) showed decreased synapse occupation by motor axons, suggesting that 
SMN is a critical component for early synapse development and maturation (28).  Temporal induction of SMN 
in SMA mice has defined a window of increased SMN production for correction of the SMA phenotype in mice 
(37, 68).  Therefore, a period during neonatal growth in the mouse constitutes a critical time for high SMN 
production.  It is increasingly clear that any potential SMA therapeutic will have maximum effect when given as 
early as possible.     
 Strategies for increasing SMN and altering the course of SMA are proliferating, including ASOs, viral 
therapy with ScAAV9-SMN, and drug compounds that induce SMN. The latter modality has the simplicity of 
application and the ability to ensure target levels within tissue. Drawbacks include non-specific targeting and 
resultant potential toxicity. Viral therapy has the distinct advantage of having the longest laboratory survival 
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increase of all interventions and the need for only a single vascular delivery (44). Disadvantages include the 
hurdles of large-scale production, as well as a patient subpopulation that is seropositive for the AAV9 capsid. 
ASOs are maturing as potential disease modifiers in SMA and other neuromuscular disease. Morpholinos have 
notable efficacy through exon skipping in Duchenne muscular dystrophy (46, 49), showing low toxicity, high 
specificity, and excellent body-wide distribution after systemic administration (46, 60, 61, 63, 76). 
Disadvantages of ASO therapy for SMA include the probability of invasive repeat CNS dosing.   
Our study has shown that a single CNS bolus of morpholino targeting ISS-N1 of SMN2 can strongly 
modulate splicing mechanics, increase SMN protein and increase survival of SMN7 SMA mice to a greater 
extent than other previously trialed ASO chemistries. Furthermore, morpholinos appear to have little or no 
toxicity when delivered at high doses within the CNS. This therapy has the potential for translation into clinical 
trials with early administration of MO via intrathecal delivery.   
Continued refinement of dosing (when, where, how much?) should continue in order to optimize 
delivery for future clinical trials. A large animal model of SMA, such as the pig, could be used to both titrate the 
optimal dosing and to truly evaluate the efficacy of peripherally administered ASO therapy for SMA in the 
setting of an intact blood-brain-barrier. It is clear that earlier correction of SMN protein levels has more 
profound effects than delayed increases, emphasizing the importance of early SMA detection and intervention 
in future clinical trial design. Methods of newborn SMA detection have been developed but implementation 
presents complications (77), including whether an SMA therapy must first demonstrate efficacy in symptomatic 
patients before the start of widespread newborn screening. We believe that new data showing both profound 
disease modification with therapy, as well as the clear advantage of pre-morbid treatment initiation, advocates 
for the start of SMA neonatal screening. 
   
Materials and Methods 
Generation of SMA Mice: SMN∆7 carrier breeding mice (SMN2+/+; Smn+/-; SMNΔ7+/+) were crossed to 
generate three types of offspring varying in mouse Smn genotype: Smn +/+, Smn +/- and Smn -/- as previously 
described (36, 39).  All breeding and subsequent use of animals in this study where approved by the IACUC of 
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The Ohio State University, Columbus, Ohio. 
 
ICV injections: The P0 or P4 pup was cryo-anesthetized and hand-mounted over a back-light to visualize the 
intersection of the coronal and sagittal cranial sutures (bregma) (55, 58).  A fine-drawn capillary needle with 
injection assembly was inserted 1 mm lateral and 1 mm posterior to bregma, and then tunneled 1mm deep to 
the skin edge (approximating) ipsilateral lateral ventricle.  An opaque tracer (Evans blue, 0.04%) was added to 
the reagent to visualize the borders of the lateral ventricle after injection of 2l of morpholino. 
 
Stereotactic injections: P30 mice were anesthetized with inhalational isoflurane (3% induction, maintenance 
1% mixed with high-flow 100% O2).  The animal was placed into the cranial stereotactic frame (Kopf 
Instruments) with digital coordinate guidance (myNeuroLab), and the anesthesia nose cone was secured.  The 
cranial apex was sterilized and a short midline incision was performed with visualization of bregma and 
lambda.  A small burr hole was drilled and cranial needle with attached Hamilton syringe was guided to 
preselected coordinates (A/P 0.58mm, D/L 2.15mm, M/L 1.10mm) for right lateral ventricle cannulation (78), 
the coordinates were validated by injection of scAAV4-GFP (ependymal localization, Fig. S3) in a trial P30 
mouse. 18цg/g of MO or scMO (equivalent to low dose (2mM) injection in the P0 pups) was injected at a rate 
of 0.75цL/min with digital microinjector (KD Scientific). After injection, the needle was withdrawn and skin 
closed with running suture. Post-surgical care was approved by the IACUC of The Ohio State University, 
Columbus, Ohio. 
 
Facial Vein Injection: Facial vein injection on P0 pups was performed as previously described (79). Mo or 
scMO was dosed at 50цg/g body mass. 
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Mouse Genotyping: The SMN2, Smn knockout allele and SMNΔ7 alleles were genotyped as previously 
described (36, 44, 57).  Tail snips were gathered at P0, each pup was identified by paw tattooing.  All 
genotyping was performed on P0 as described previously (44).  
 
Behavioral analysis: All injected animals, as well as breeding pairs, were monitored each day for morbidity, 
mortality, and new litters.  Control and experimental animals were weighed each day, and righting response 
was assessed during the animals’ first 21 days as previously described (80).  Grip strength was recorded as 
previously described with correction for the weight of the animals (81). 
 
RT-PCR and Real-Time RT-PCR analysis: RNA was isolated from Trizol (Invitrogen) homogenized tissue 
and purified with the RNeasy kit (Qiagen).  RT-PCR was performed as previously described (57).  The SMNΔ7 
transgene lacks the terminal portion of exon 8.  Primers were designed to amplify only the SMN2 transcripts 
that contain this region, thus distinguishing SMNΔ7 from SMN2: (hSMN2E8rev) 
TTATATACTTTTAAACATATAGAAGATAG, (hSMNE6fwd) AGATTCTCTTGATGATGCTGAATG.    
Real-time RT-PCR assayed for full-length SMN2 transcripts relative to cyclophilin.  SMN2 amplification: 
(hSMNFull Fb) GTTTCAGACAAAATCAAAAAGAAGGA, (hSMNFull Rc) 
TCTATAACGCTTCACATTCCAGATCT, probe: (hSMNFull FAM) ATGCCAGCATTTCTCCTTAATTTAAGG.  
Cyclophilin: (QcycloF) GTCAACCCCACCGTGTTCTT, (QcycloR) TTGGAACTTTGTCTGCAAACA, probe: 
(Probecyclo NED) CTTGGGCCGCGTCT. PCR reaction for SMN2 used 2 l cDNA, 0.6 l (300nm) forward and 
reverse primer; cyclophilin, 1.8 l (900nM) forward and reverse primer. Transcript level was determined as 
previously described (82). 
 
Digital Droplet PCR: cDNA was collected as detailed above.  Identical primers and probe were used for 
ddPCR as was used for real time RT-PCR.  The PCR reaction for SMN2 used 1.0 l cDNA and cyclophilin 
used 0.1 l. 1.8 l (900nm) forward and reverse primer was used for both SMN2 and cyclophilin.  Droplet 
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generation and reader analysis were performed on QuantaLife (www.quantalife.com/, now Bio-Rad) hardware. 
Ten to fifteen thousand droplets containing cDNA transcript and PCR reagents were generated before 
amplification. Transcript concentration was first calculated by the droplet reader using poisson statistical 
distributions (65), and relative SMN2 levels were determined by calculating the ratio of SMN2 versus 
cyclophilin.  
 
Western: Western blot analysis was performed as previously described (36, 37, 57).  Detection was performed 
using the LI-COR Odyssey Imaging System (Biosciences) and quantification was determined using Odyssey 
Infrared Imaging System Application Software (Biosciences). 
 
Morpholino ASO Preparation: The MO sequence, numbered from the SMN2 exon 7 donor site (Figure 1), 
was ATTCACTTTCATAATGCTGG (MWT=6754, Gene Tools).  scMO sequence was 
TCCTTTAAAGTATTGTGACC (MWT=6754, Gene Tools).  Morpholinos were resuspended in sterile 0.9% 
sodium chloride, aliquoted, and mixed with Evans Blue (final concentration 0.04%).  Three different molar 
concentrations were prepared (High: 6mM=40.5g/L; Middle: 4mM=27g/L; Low: 2mM =13.5g/L).  Stock 
solutions were stored at -20oC, working solutions at 4oC.  Lissamine tagged morpholino (sequence 
CCTCTTACCTCAGTTACAATTTATA) was resuspended to 2mM in 0.9% NaCl.   2l of morpholino oligomer 
was injected, yielding total doses per animal of 81g (High), 54g (Middle) and 27g (Low). 
 
SMN Immunofluorescence:  SMNΔ7 SMA mice (SMN2+/+; HB9:GFP; Smn-/-; SMNΔ7+/+) were injected by 
P0 ICV with 4mM MO. Carrier control was not injected. Spinal cords were harvested, frozen, fixed and 
sectioned at P7 as previously described (37). Tissue sections were stained with anti-human SMN KH antibody 
1:10 overnight and Alexa Fluor® 594 goat anti-rabbit IgG (Molecular probes) (1:1000). Endogenous lissamine 
(RFP) and GFP fluorescence were imaged with a Nikon E800 Eclipse fluorescent microscope, Ultrapix Digital 
Camera (Olympus) with MagnaFIRE v2.1C software (Optronics), and further processed with Adobe Photoshop 
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CS2.   
 
Statistical Analysis:  
Data are expressed as means+/- standard errors.  Kaplan-Meier curves were generated from the survival data 
and tested using the Mantel-Cox log rank test.  All statistical analyses were performed with SPSS v.16.0. 
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Figure Legends 
 
 
Figure 1. Illustration of SMN2 exon and intron 7 with highlighted ISS-N1 and the target site for morpholino 
HSMNEx7D(-10-29) (MO).   
 
Figure 2. Analysis of exon 7 incorporation in SMN2 transcript.  Smn +/-; SMN2 +/+; 7SMN +/+ mice were 
injected by P0 ICV with low (27цg), middle (54ug), or high dose (81цg) MO.  RNA from brain (A) and spinal 
cord (B) tissue was isolated and cDNA amplified with SMN2 specific primers.  All dosings show increased full-
length SMN2 (top band) versus exon 7 deficient SMN2 (bottom band) at all time points (P7, P21, P45, P65) 
relative to scramble morpholino control (scMO) injected animals (HiC=16 copies SMN2 (8SMN2+/+; Smn-/-); 
WT=Wild Type).  (C) Digital droplet PCR for relative full-length SMN2 (FL-SMN2) relative to cyclophilin; 
low, middle, high dose MO (dose response curve); P7 brain and spinal cord tissue.   (D)  Quantitative RT-PCR 
for full-length SMN2 in spinal cord P7-P65 (low, middle, high dose).  There is increased P7 full-length SMN2, 
with decay at later time points.   
 
Figure 3.  Central vs. peripheral SMN2 splice modulation. (A) RT-PCR systemic analysis of full-length SMN2 
after P0 MO ICV injection.  There is no increased SMN2 exon 7 incorporation in visceral structures (heart, 
liver, kidney) as compared to spinal cord (n=2). (B) Digital droplet PCR (Full-Length SMN2 relative to 
cyclophilin) of brain, spinal cord, heart, and liver after P0 MO ICV (54 µg) or P0 facial vein (50 µg/g) injection 
in Smn +/-; SMN2 +/+; 7SMN +/+ mice. Results per organ are relative to Scramble injected control, which 
has been set at 1 on the y-axis. There is increased CNS splice modulation after both ICV and peripheral dosing.  
There is no increased splicing in the heart and liver after ICV injection, suggesting limited translocation across 
the CSF-blood barrier or rapid systemic degradation.  (C)  Digital droplet PCR (FL-SMN2 relative to 
cyclophilin) of brain, spinal cord, heart and liver after P0 MO ICV (54 µg) injection in Smn -/-; SMN2 +/+; 
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28 
7SMN +/+ mice; SMA scramble injected control per each organ. Results are displayed as absolute relative 
ratios on the y-axis. There are large increases in CNS splice modulation, and a more modest increase in liver 
full-length SMN2. 
 
Figure 4.  Analysis of SMN induction after MO delivery.  Smn +/-; SMN2 +/+; 7SMN +/+ mice were injected 
by P0 ICV with low (27цg), middle (54ug), or high dose (81цg) MO.  Quantification of SMN by human 
specific antibody relative to actin in brain (A) and spinal cord (B) for each dose at P7, P21, P45 and P65.  All 
doses increased P7 SMN (strongest increase with high dose) and decay through P65 (n=3 for each dose per time 
point).  (C-D)  Representative Western blots for human SMN and actin in brain (A) and spinal cord (B) after 
low dose injection.  
 
Figure 5. Motor neuron SMN expression increases in MO injected 7SMN SMA mice. (A-C) 54ug MO 
(middle) dose was injected by P0 ICV.  Lumbar spinal cord tissue was harvested at P7, sectioned and stained 
with human specific anti-SMN KH antibody. (A) Motor neurons in the ventral horn were identified by 
HB9:GFP transgenic expression. (B) SMN is found in the cytoplasm and in gems in the nucleus of motor 
neurons, as well as other cell types, throughout the spinal cord. Insert highlights the motor neuron indicated by 
the arrowhead.  (C) Merged image of SMN expression (red) in the motor neuron (green). Insert highlights the 
motor neuron indicated by the arrowhead. (D,E,F)  SMN expression in a non-injected carrier control animal. 
(D) Motor neurons identified by HB9:GFP expression. (B) A low level of SMN expression from SMN2 is 
present throughout the spinal cord. (C) Merged image of SMN expression (red) in the motor neuron (green).  
Scale bar = 200 µm. 
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Figure 6. Survival and weight gain are increased in MO treated 7SMN SMA animals.  (A) Kaplan-Meier 
survival curve for low (n=8), middle (n=10), and high dose (n=13).  Median survival for low (83+/-37.7 days, 
max 161), middle (104+/-15.0 days, max 148) and high dose (112+/-6.6 days, max 153) were not statistically 
different (Log Rank p>0.8 for all pairwise comparisons).  Median survival for each group was significantly 
extended when compared with scMO (6mM, 81µg) injected 7SMN SMA animals (15+/-1.1 days, Log Rank 
p<0.001 for all pairwise comparisons).  (B)  MO treated 7SMN SMA mice increased mass nearly parallel to 
that of control animals (Smn +/+; SMN2 +/+; SMN7 +/+, scMO injection) through ~P30, at which point the 
mass curves leveled while control animals continued to gain weight.  P80 mean: Low dose=16+/-0.9g, Middle 
dose: 17+/-0.6g, High dose: 19+/-1.9g, Control=22+/-1.4g.  (C)  Kaplan-Meier survival curve after 5 µg (n=4) 
and 10 µg (n=3) MO ICV P0 injection (censored, through P30). 
 
Figure 7: Treated SMA animals have an improved motor phenotype.  (A) Righting response quickly approaches 
100% by P3 in ICV MO treated animals, while scMO injected SMN7 SMA animals have a rapid decline in 
righting ability during the first week of life.  No SMA animals injected with scMO were able to right after P6.  
(B) Mass corrected forelimb and hindlimb grip strength is equivalent between control animals (Smn +/+; SMN2 
+/+; SMN7 +/+, scMO injection) and MO treated SMN7 SMA animals (grip strength assessed at P30 in 
Newtons/mg body mass; Forelimb: Control 34.5+/-2.2 vs. SMA 34.2+/-2.1, Hindlimb: Control 28.2+-5.0 vs. 
SMA 25.8+/-4.4). 
 
Figure 8.  Alternative MO injection strategies do not increase survival beyond P0 ICV MO injection.  Three 
cohorts of mice each received an injection of MO by P0 facial vein (50 µg/g body mass, n=3), P0 facial vein 
and ICV (50 µg/g peripheral, 54 µg ICV, n=5), or P0 and P30 ICV (with stereotactic guidance, 54 µg/g P0, 18 
µg/g P30, n=4).  Survival for all groups was equivalent to high dose P0 ICV MO injection (Log Rank p>0.09) 
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Figure 9.  Delayed ICV injection yields intermediate weight gain and survival.  (A) SMN7 SMA mice treated 
at P4 with 54g MO per gram body mass (‘high dose’ equivalent) had increased weight gain compared to 
SMN7 SMA controls, but was less than the weight gain displayed by P0 MO treated SMN7 SMA animals 
(P30 Mean 10.6+/-1.5g (P4) vs. 13.6+/-1.0g (P0)).  (B) P4 ICV MO injected animal survival was also increased 
(median 41+/-14.2 days, maximum 78 days) compared to scMO injected animals (15+/-1.1 days; Log Rank 
p<0.001), but was decreased compared to SMN7 SMA animals treated at P0 with high-dose MO (112+/-6.6 
days, maximum 153 days, Log Rank p<0.01).  (C) SMN7 SMA mice were injected with P4 MO by facial 
vein. Survival was modestly extended compared to scMO injected animals, and there was a decreased survival 
compared to animals injected by P4 ICV MO (median 21+/-.354 days, Log Rank p<0.014). 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
31 
 
 
 
Fig. 1 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
32 
 
 
Fig. 2 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
33 
 
 
Fig. 3 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
34 
 
 
Fig. 4 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
35 
 
 
 
Fig. 5 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
36 
 
 
Fig. 6 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
37 
 
 
Fig. 7 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
38 
 
 
 
Fig. 8 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
39 
 
 
Fig. 9 
 
 at M
urdoch U
niversity on M
arch 13, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
